Gu'an Dingtai Haigui Biotechnology

Gu'an Dingtai Haigui Biotechnology is a clinical-stage biotechnology company based in Gu'an, Hebei, China, specializing in the development of therapeutic DNA vaccines for oncology and immune system diseases. The company's lead candidate, pNMM, is a nude plasmid DNA vaccine targeting a fusion of tumor-associated antigens (NY-ESO-1, MAGE-A3, and MUC1) and is currently in Phase 1 clinical trials for advanced solid tumors and lymphomas. Utilizing its proprietary pSFVK1 vector platform and IRES-based expression technology, the company focuses on enhancing the immunogenicity and anti-tumor efficacy of DNA-based therapies. Gu'an Dingtai Haigui operates within the Peptide Valley Biomedical Incubation Port and leverages the expertise of overseas returnee scientists to advance its innovative pipeline. The company's research has demonstrated significant anti-tumor effects in preclinical models, supporting its transition into human clinical studies.